ProNAi Therapeutics (DNAI) Misses Q2 EPS by 5c

ProNAi Therapeutics (NASDAQ: DNAI) reported Q2 EPS of ($0.43), $0.05 worse than the analyst estimate of ($0.38).

At June 30, 2016, ProNAi had $130.6 million in cash and cash equivalents compared to $150.2 million in cash and cash equivalents at December 31, 2015.

For earnings history and earnings-related data on ProNAi Therapeutics (DNAI) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Lakeland Bancorp (LBAI) Tops Q1 EPS by 1c
• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance